Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CK 0803

Next Previous
Drug Profile

CK 0803

Alternative Names: CK-0803

Latest Information Update: 29 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cellenkos
  • Class Antiparkinsonians; T lymphocyte cell therapies
  • Mechanism of Action Regulatory T-lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Amyotrophic lateral sclerosis
  • Preclinical Chronic inflammatory demyelinating polyradiculoneuropathy; Parkinson's disease

Most Recent Events

  • 22 Apr 2025 Efficacy and adverse event data from the phase Ib REGALS trial in Amyotrophic lateral sclerosis released by Cellenkos
  • 31 Aug 2023 Preclinical trials in Parkinson's disease in USA (Parenteral) (Cellenkos pipeline, August 2023)
  • 03 Apr 2023 Cellenkos initiates a phase I REGAL trial for Amyotrophic lateral sclerosis (In adults, In the elderly) in USA (IV, Infusion) (NCT05695521)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top